Add Company
Join Now

Convergent Therapeutics Revenue and Competitors

License our Company Data API

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Convergent Therapeutics's estimated annual revenue is currently $1.4M per year.(i)
  • Convergent Therapeutics's estimated revenue per employee is $77,500

Employee Data

  • Convergent Therapeutics has 18 Employees.(i)
  • Convergent Therapeutics grew their employee count by 200% last year.

Convergent Therapeutics's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Convergent Therapeutics?

Convergent Therapeutics is a clinical-stage biotechnology company exploring the full potential of dual-targeted combination strategies to treat cancer. Convergent has developed a therapeutic platform that is capable of targeting validated and novel cancer antigens. Building on breakthrough research developed by Dr. Neil Bander at Weill Cornell Medicine, Convergent has demonstrated that dual targeting of surface cancer molecules like Prostate-Specific Membrane Antigen (PSMA) improves antitumor efficacy. By leveraging targeting agents with different bio-distributions, such as monoclonal antibodies and ligands, supra-additive therapeutic doses are delivered to tumor cells without additive toxicity to the patient.

keywords:N/A

N/A

Total Funding

18

Number of Employees

$1.4M

Revenue (est)

200%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$14.1M18-10%$161M
#2
$3.5M18N/AN/A
#3
$1.6M18N/AN/A
#4
$2.5M18-14%N/A
#5
$3.5M18-40%N/A